Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| HCC1954 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8349 | -0.0093 | -0.0064 | 1.3800 | 7.2097 | 0.65841 |
| CAL-85-1 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0418 | -0.0009 | 0.0000 | Inf | -4.681 |
| HCC1806 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 1.0500 | -0.0207 | -0.0033 | 0.0000 | Inf | -0.67606 |
| SUM159PT | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9906 | -0.0088 | -0.0001 | 0.0000 | Inf | -0.54094 |
| HCC1806 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.8168 | 0.1972 | 0.0004 | 0.0000 | Inf | -2.9998e-08 |
| SUM159PT | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.6876 | 0.3173 | -0.0017 | 0.0000 | Inf | 0.45421 |
| HCC1806 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9819 | -0.0154 | 0.0035 | 0.0000 | Inf | -0.19348 |
| CAL-120 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.6687 | 0.1422 | 0.0012 | 1.4451 | 0.023318 | 0.96675 |
| HCC1806 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9450 | 0.0145 | -0.0020 | 0.0000 | Inf | 0.32254 |
| CAL-120 | A-1210477 | Mcl-1 | Misc | Inf | 0.9427 | 0.0152 | 0.0003 | 0.0000 | Inf | 0.34764 |
| HCC1806 | A-1210477 | Mcl-1 | Misc | Inf | 0.9047 | -0.0078 | 0.0015 | 4.2962 | 12.7646 | 0.58471 |
| HCC1806 | Trametinib | MEK | MAPK/nRTK | Inf | 0.7036 | 0.1086 | 0.0280 | 4.8006 | 0.007609 | 0.89189 |
| SK-BR-3 | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.1182 | 0.7944 | 0.1209 | 0.1000 | 6.3064e-07 | 0.84606 |
| T47D | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.2975 | 0.6157 | 0.0150 | 0.1000 | 5.9599e-07 | 0.77906 |
| CAMA-1 | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.1642 | 0.7666 | 0.0258 | 0.1000 | 1.9385e-07 | 0.61758 |